Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/08/2022* -- Results Q3 2022 -- -1.81 --
11/08/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.82 -1.88 56.39%
08/09/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/09/2022 -- Results Q1 2022 -1.94 -1.40 -39.02%
05/09/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/28/2022 -- Results Q4 2021 -1.47 -1.69 13.04%
02/28/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/08/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/09/2022
Beat/Miss Upgrade
Return Since -11.57%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
URL https://www.arcturusrx.com
Investor Relations URL https://ir.arcturusrx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
68.36%
-66.56%
-45.92%
-43.02%
140.0%
299.1%
-14.68%
-56.44%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
--
--
--
--
--
--
--
-66.92%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-38.83%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
25.05%
-61.17%
-88.94%
-77.05%
-79.57%
12.53%
-8.16%
83.59%
-25.73%
As of October 05, 2022.

Profile

Edit
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
URL https://www.arcturusrx.com
Investor Relations URL https://ir.arcturusrx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
TYNE 94190.00 USD 5.99%
MSGR 157479.0 USD 4.50%
MOON 1.023M USD 2.45%
F000016ZDA 242.00 USD 2.42%
F00001CY0W 167.00 USD 1.67%
EAGB.NO 213692.0 USD 1.36%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ARCT Tweets